爱泌罗的功效与作用

Amirol's common name is pentosan polysulfate sodium, which is a semi-synthetic macromolecular carbohydrate derivative with a similar structure to glycosaminoglycans.

As a type of low molecular weight heparin-like compound, Almirol has certain anticoagulant and fibrinolytic effects, but its exact mechanism in the treatment of interstitial cystitis is not completely clear.

Efficacy and role of Amirol

Based on preliminary clinical model verification, it can adhere to the mucosal surface of the bladder wall, allowing it to act as a buffer to control cell permeability.

This can prevent various highly irritating solutes in urine from reaching the cells of the bladder, thereby reducing or preventing inflammation and pain in the urinary tract.

Preclinical studies have shown that parenterally administered radioactively labeled pentosan polysulfate sodium is mainly distributed in the urothelium of the genitourinary tract, and to a lesser extent in the liver, spleen, lungs, skin, periosteum and bone marrow. Its specific effect on bladder tissue may also be related to its widespread distribution in the urothelium.

Clinical efficacy of Almiro

Based on numerous clinical studies, it has been confirmed that Almiro has a significant alleviation effect on bladder pain and discomfort caused by interstitial cystitis, especially for chronic and recurring bladder pain and discomfort, and the effect becomes more obvious as the treatment time is extended.

Elmiron pictures come from public channels (such as the official website of the FDA, the official website of the original pharmaceutical manufacturer, etc.) and are for reference only.

Amirol Medication Guide

1. Recommended dosage

300 mg/day, take 100 mg capsule orally three times a day.

2. How to take the medicine

The capsule should be taken with water, at least 1 hour before or 2 hours after a meal.

3. Post-medication evaluation

Patients should be re-evaluated after 3 months of treatment with Amirol. If improvement has not occurred and there are no limiting adverse events, Almirol can be continued for an additional 3 months.

4. Long-term medication evaluation

For patients whose pain does not improve within 6 months, the clinical value and risks of continuing Almirol treatment are unclear.

Precautions for the use of Almiro in special groups

1. Elderly patients or patients with liver and renal insufficiency

The pharmacokinetics of pentosan polysulfate sodium have not been specifically studied in these groups. Since there is evidence that the liver is involved in the elimination process of Almiro, hepatic insufficiency may affect its pharmacokinetics, so caution should be used when using it in these patient groups.

2. Pregnant women

Reproduction studies have shown that there is no evidence that Almirol damages fertility or causes harm to the fetus.

Because animal studies are not always predictive of human response, this drug should be used during pregnancy only when clearly needed.

3. Breastfeeding women

It is unclear whether this drug will be excreted into human milk, so caution should be used when giving it to breastfeeding women.

4. Children

The safety and effectiveness of Amirol in pediatric patients under 16 years of age have not been determined, so use in this age group is not recommended.

Drug interactions of Almirol

Studies have shown that there is no significant pharmacokinetic interaction between Almirol and warfarin. Concomitant use of Almirol 100 mg capsules every 8 hours for 7 days in healthy subjects receiving warfarin and adjusted to an international normalized ratio (INR) of 1.4 to 1.8.

The pharmacokinetic parameters of R-warfarin and S-warfarin are similar in the presence and absence of pentosan polysulfate sodium.